Dose-ranging trial initiated in early 2013.

Related StoriesUniversity of Leicester awarded BBSRC grant to explore three important areas that impact individual healthUsing smartphone to identify diabetes marker in salivaLiposomal sizing and the Coulter theory: an interview with Professor Melvin E. Klegerman Completing enrollment in this trial before schedule represents a significant achievement for the program, stated Ryo Kubota, MD, PhD, Chairman, President and CEO, Acucela Inc.Alphaject coats the tumour cells in alphagal, presenting a foreign antigen to the disease fighting capability thereby. This is thought to bring in regards to a 'hyper-severe rejection' of the tumour, and breaks the immune tolerance shielding the tumour from assault, allowing the disease fighting capability to both start to destroy the tumour instantly and to confer a long-enduring protection over time in the form of improved immune surveillance. The effect can be analogous to a personalised malignancy vaccine, acting continuously to prevent both metastasis and recurrence. Mike Westby, CEO of Agalimmune, commented: ‘The development of immunomodulatory therapies is an exciting and rapidly emerging field, that may result in improved anti-cancer treatments for patients hopefully.